– This financing round was carried out by UI Investissement (via the Pertinence Invest 2 fund, advised by Mérieux Equity Partners), Elaia and GO Capital, with the participation of a major player in ophthalmology, Unither Pharmaceuticals, and HTL Biotechnology, the world leader in the development and bioproduction of pharmaceutical-grade biopolymers.
– The funds will finance the first-in-man clinical trial of topical ophthalmic inserts revolutionising the treatment of glaucoma, as well as the preclinical development of a second programme in macular oedema, targeting the two main causes of blindness.
– BIOPHTA’s unique technology is transforming the treatment of both the anterior and posterior segments of the eye. The company is developing the first continuous topical retinal treatment to free patients from intraocular injections.